Analyst Price Targets — SKYE
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| October 6, 2025 4:12 pm | — | Craig-Hallum | $2.00 | $1.88 | TheFly | Skye Bioscience downgraded to Hold from Buy at Craig-Hallum |
| October 6, 2025 2:19 pm | — | Cantor Fitzgerald | $2.00 | $2.12 | TheFly | Skye Bioscience downgraded to Neutral from Overweight at Cantor Fitzgerald |
| September 10, 2024 4:30 am | Jonathan Wolleben | JMP Securities | $15.00 | $6.35 | TheFly | Skye Bioscience initiated with an Outperform at JMP Securities |
| August 26, 2024 8:15 am | Albert Lowe | Craig-Hallum | $18.00 | $5.97 | StreetInsider | Craig-Hallum Reiterates Buy Rating on Skye Bioscience (SKYE) |
| June 10, 2024 5:17 pm | Jay Olson | Oppenheimer | $21.00 | $9.98 | StreetInsider | Skye Bioscience (SKYE) PT Lowered to $21 at Oppenheimer |
| May 23, 2024 6:05 am | Kristen Kluska | Cantor Fitzgerald | $21.00 | $11.98 | TheFly | Skye Bioscience initiated with an Overweight at Cantor Fitzgerald |
| April 11, 2024 4:14 pm | Jay Olson | Oppenheimer | $25.00 | $12.69 | StreetInsider | Oppenheimer Starts Skye Bioscience (SYKE) at Outperform Following Uplisting to Nasdaq (correction) |
| March 14, 2024 10:41 am | Edward Tenthoff | Piper Sandler | $20.00 | $12.90 | StreetInsider | Skye Bioscience (SKYE) PT Raised to $20 at Piper Sandler |
Latest News for SKYE
SAN DIEGO, May 20, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ: SKYE), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, today announced that the Cohort Review Committee (CRC) responsible for reviewing safety data generated from the CBeyond Part C Expansion Study, and for approving the opening of enrollment in Cohort 2…
SAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye” or the “Company”), a clinical stage biotechnology company developing next-generation molecules that modulate G-protein-coupled receptors to treat obesity, overweight, and related conditions, today reported financial results for the first quarter ended March 31, 2026, along with recent business updates and anticipated milestones.
SAN DIEGO, May 11, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye” or the “Company”), a clinical stage biotechnology company developing next-generation molecules that modulate G-protein-coupled receptors to treat obesity, overweight, and related conditions, today reported financial results for the first quarter ended March 31, 2026, along with recent business updates and anticipated milestones.…
NEW YORK, April 22, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Skye Bioscience, Inc. (NASDAQ: SKYE) breached their fiduciary duties to shareholders.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for SKYE.
U.S. House Trading
No House trades found for SKYE.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.